AIMD.P AIM4 Ventures

Annovis Bio to Present at the 2020 BIO Investor Forum

Annovis Bio to Present at the 2020 BIO Investor Forum
EN
12/10/2020

Underlying

AIMD.PAIM4 Ventures

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM4 Ventures

 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Appoints Mark Guerin as Chief Financial Officer

Annovis Appoints Mark Guerin as Chief Financial Officer MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer (CFO) to help lead the Company through a pivotal phase as buntanetap continues to show promise in late-stage clinical development. Mr. Guerin has extensive experien...

19h / 50m 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetic...

Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap MALVERN, Pa., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of a new article in a peer-reviewed journal , which describes the pharmacokinetic (PK) profile of a new crystal form of buntanetap and compares it to the old form across several s...

September 16, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis to Present at the H.C. Wainwright 27th Annual Global Investmen...

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference happening September 8-10, 2025 in Lotte New York Palace Hotel, New York City. Presentation details ...

September 2, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Fin...

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results. “In the past quarter, our efforts were centered on driving enrollment for the pivotal Phase 3 trial in early AD, which now includes 76 secured clinica...

August 12, 2025 1 EN
 PRESS RELEASE
Free
AIMD.P AIM4 VENTURES

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Annovis Completes Full Patent Transfer to Crystal Buntanetap Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both forms are covered by a total of 13 patent families. All patents are filed internationally, securing global coverage of buntanetap. MALVERN, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch